A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 25 Oct 2016
At a glance
- Drugs Alisertib (Primary) ; Abiraterone acetate; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 10 May 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Jun 2014 The trial design presented at 50th Annual Meeting of the American Society of Clinical Oncology.